A Picture of Prostate Cancer in Europe

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

HAMBURG-The Federation of European Cancer Societies released information on prostate cancer in Europe at its biennial European Cancer Conference (ECCO 9).

HAMBURG—The Federation of European Cancer Societies released information on prostate cancer in Europe at its biennial European Cancer Conference (ECCO 9).

  • In Europe, one man in 11 is diagnosed with prostate cancer, which accounts for 13% of all new cancer diagnoses and almost 9% of cancer deaths.
  • The death rate tends to be highest in northern European countries and lowest in southern and eastern Europe.
  • Death rates from prostate cancer have risen dramatically in recent years, probably because of the increasing number of elderly men in the population. In England and Wales, for example, there were 4,313 deaths attributed to prostate cancer in 1974, compared with 8,735 in 1992, a 103% increase in only 17 years.
Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Related Content